Study summary · research use only
[Radioprotective effect of synthetic immunomodulators on hemopoietic CFU-S]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study, in which the species was not specified, the radioprotective effect of the synthetic peptide immunomodulators thymogen (Glu-Trp) and thymohexin (Arg-Lys-Asp-Val-Tyr-Arg) on hemopoietic CFU-S was investigated. The abstract reports both thymogen and thymohexin reduced the damaging effect of ionizing radiation (1 Gy) on CFU-S by half, and that treatment with these preparations after irradiation at a dose of 4 Gy led to more intensive restoration of the CFU-S population compared with control.
Abstract
The radiotherapeutic effect of thymogen (Glu-Trp) and thymohexin (Arg-Lys-Asp-Val-Tyr-Arg) synthetic peptide immunomodulators was investigated. Both thymogen and thymohexin were demonstrated to be able to reduce the damaging effect of ionizing radiation (1 Gy) on CFU-S by half. The treatment by these preparations after irradiation at dose of 4 Gy leads to more intensive restoration of CFU-S population as compared with control.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.